Bone Biologics Corporation (BBLGW)

Market Cap	2.15M -27.1%
Revenue (ttm)	n/a
Net Income	-3.95M
EPS	-4.77
Shares Out	1.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3
Open	42.50
Previous Close	31.95
Day's Range	42.50 - 42.50
52-Week Range	8.30 - 42.50
Beta	1.28
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 20, 2026

About BBLGW

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company’s lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company’s NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interven...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2004
• Employees: 2
• Stock Exchange: NASDAQ
• Ticker Symbol: BBLGW
• Website: https://www.bonebiologics.com